|
|
Congressional debt panel meeting in secret, looking at Medicare/Medicaid cuts. |
|
Kaiser: The 'super committee' is taking a look at proposals to reduce spending on this population, which qualifies for both Medicare and Medicaid and is made up of the sickest and poorest American citizens. In the background, the New York Times examines what congressional "short-term fixes" say about the legislative body.
|
|
|
Saw palmetto no more effective than placebo for urinary tract symptoms. |
|
Science Blog: Saw palmetto, a widely used herbal dietary supplement, does not reduce urinary problems associated with prostate enlargement any better than a placebo, according to research funded by the National Institutes of Health. The study was published Sept. 28 in the Journal of the American Medical Association.
|
|
Prestart nutrition care associated with better survival during 1st year of dialysis therapy. |
|
AJKD: Conclusions. Our study suggests an independent association between predialysis dietitian care for more than 12 months and lower mortality during the first year on dialysis therapy.
|
|
Dr. Barry Straube honored with AAKP award. |
|
Marketwatch: Barry M. Straube, M.D., a member of its Board of Directors, was honored with the Peter Lundin, MD Award from the American Association of Kidney Patients (AAKP) at the organization's 38th Annual Convention in August.
|
|
Hb target of 11-13 better than 9-11 in predialysis CKD patients accoding to a Japanese randomized trial |
|
Akizawa et al (Therap Apher Dial): Abstract -- Correcting anemia in patients with chronic kidney disease (CKD) to higher hemoglobin (Hb) levels may be associated with increased risk. No optimal target for Hb has been established. This controlled study examined 321 patients with CKD who were not on dialysis, had a Hb level of <10 g/dL, and a serum creatinine of 2.0 to 6.0 mg/dL. They were randomized into two target Hb groups: 161 to high Hb (11.0–13.0 g/dL) to receive darbepoetin alfa and low Hb to 160 (9.0–11.0 g/dL) to receive recombinant erythropoietin. The study lasted 48 weeks. Of 154 and 153 patients with adverse events, cardiovascular adverse events developed in 42 and 51 patients in the high and low Hb groups, respectively, with no significant difference in the incidence. All quality of life scores improved in the high Hb group and vitality improved significantly more with high Hb (P = 0.025). The left ventricular mass index (LVMI) remained stable in the low Hb group, but there was a significant decrease in LVMI in the high group (P < 0.001). There were no safety concerns with targeting a higher Hb level during the 48 weeks of this study. Patients with a higher Hb target had comparatively better outcomes with respect to quality of life and LVMI.
|
|
|
|
|
<< Start < Prev 671 672 673 674 675 676 677 678 679 680 Next > End >>
|
|
Page 675 of 2630 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
